XPRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. Despite a still-bullish moving-average stack, momentum is fading (MACD contracting), there’s no Intellectia buy signal to lean on, hedge funds are selling aggressively, and the latest Wall Street downgrade carries a $13 target well below the current $16.01. For an impatient buyer seeking immediate upside without waiting for a cleaner setup, the risk/reward is unfavorable at this level near resistance (~$16.58) and ahead of earnings (2026-02-19).
Trend is modestly bullish but losing steam. Price ($16.01) is just above the pivot ($15.945), suggesting a near-term decision point. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), supporting the broader uptrend. RSI(6)=56 is neutral (no oversold bounce signal). MACD histogram is slightly positive (0.00964) but positively contracting, implying upside momentum is weakening. Key levels: Support S1 $15.309 (then S2 $14.916); Resistance R1 $16.581 (then R2 $16.974). Pattern-based odds suggest mild upside bias (next day +0.64% / next week +0.73% / next month +2.38%), but not strong enough to override bearish positioning/ratings.
Intellectia Proprietary Trading Signals
on 2026-02-19 pre-market could re-rate the stock if results/outlook surprise to the upside (Street EPS est. 0.15). Technical trend remains supported by bullish moving averages, which can help dips hold above ~$15.31 support.
Analyst downgrade risk overhang: Piper Sandler downgraded to Underweight with a $13 target, citing weak 2026 growth setup and downside to estimates. Hedge funds are selling (selling amount +152.67% QoQ), a meaningful negative positioning signal. No supportive news flow in the past week to offset the downgrade/flow pressure. If price loses the pivot (~$15.95), a quick move toward $15.31 support becomes more likely.
Latest reported quarter: 2025/Q3. Revenue was $411.356M (-2.71% YoY), Net Income $13.963M (-14.21% YoY), EPS $0.12 (-14.29% YoY). A bright spot was Gross Margin improving to 13.13 (+2.74% YoY), but overall the quarter shows decelerating/negative YoY growth in top line and earnings—more consistent with a ‘wait for clearer growth’ story than an immediate buy setup.
Recent trend turned more cautious. Goldman Sachs (2025-11-05) kept Neutral and raised PT to $15 (from $12). Piper Sandler (2025-12-18) downgraded to Underweight with PT $13 unchanged, explicitly framing 2026 as a transition year with the offshore inflection pushed to 2027 and citing valuation after a strong 6-month run. Wall Street pros/cons: Pro—recognized improvement vs prior expectations (GS PT raise). Con—near-term growth visibility questioned, valuation risk highlighted, and the latest PTs ($13–$15) sit below the current ~$16, implying limited upside and meaningful downside per sell-side framing.
